Anatara Lifesciences Ltd (ASX: ANR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Anatara Lifesciences Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $8.03 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 191.14 million
Earnings per share -0.013
Dividend per share N/A
Year To Date Return 81.82%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Anatara Lifesciences Ltd (ASX: ANR)
    Latest News

    investor looking excited at rising fortescue share price on laptop
    Share Market News

    Why the Anatara (ASX:ANR) share price is rocketing 19% today

    The Anatara Lifesciences Ltd (ASX: ANR) share price is one of the best performers on the ASX today. Here's what…

    Read more »

    a woman
    ⏸️ Investing

    5 multi-million dollar takeover targets

    The falling Australian dollar and cheap debt could make Mortgage Choice Limited (ASX:MOC), Treasury Wine Estates Ltd (ASX:TWE), Challenger Ltd…

    Read more »

    a woman
    ⏸️ Investing

    Ham and pineapple could make Anatara Lifesciences Ltd the next CSL Limited 

    Successful trials de-risk the hidden gem that is Anatara Lifesciences Ltd (ASX:ANR).

    Read more »

    a woman
    ⏸️ Investing

    10 stocks up by more than 50% in the past month

    The market has gone nowhere in the past month, but these 10 stocks are up by more than 50%

    Read more »

    ANR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Anatara Lifesciences Ltd

    Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.

    ANR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 May 2024 $0.04 $0.00 0.00% 85,129 $0.04 $0.04 $0.04
    17 May 2024 $0.04 $0.00 0.00% 20,000 $0.04 $0.04 $0.04
    16 May 2024 $0.04 $0.00 0.00% 71,381 $0.04 $0.04 $0.04
    13 May 2024 $0.04 $0.00 0.00% 31,000 $0.04 $0.04 $0.04
    10 May 2024 $0.04 $0.00 0.00% 40,000 $0.04 $0.04 $0.04
    09 May 2024 $0.04 $0.01 27.78% 93,453 $0.04 $0.04 $0.04
    08 May 2024 $0.04 $-0.01 -21.74% 201,969 $0.04 $0.04 $0.04
    07 May 2024 $0.05 $0.00 0.00% 34,734 $0.05 $0.05 $0.05
    06 May 2024 $0.05 $0.00 0.00% 338,192 $0.05 $0.05 $0.05
    03 May 2024 $0.05 $0.00 0.00% 8,000 $0.05 $0.05 $0.05
    02 May 2024 $0.05 $0.00 0.00% 42,041 $0.05 $0.05 $0.05
    01 May 2024 $0.05 $0.00 0.00% 424,486 $0.05 $0.05 $0.05
    26 Apr 2024 $0.05 $0.00 0.00% 506,975 $0.05 $0.05 $0.05
    24 Apr 2024 $0.05 $0.00 0.00% 111,942 $0.05 $0.05 $0.05
    23 Apr 2024 $0.04 $0.00 0.00% 22,046 $0.04 $0.04 $0.04

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    11 Dec 2023 David Brookes Issued 750,000 $16,500
    Rights issue.
    11 Dec 2023 David Brookes Issued 750,000 $16,500
    Rights issue.
    11 Dec 2023 John Michailidis Issued 250,000 $5,500
    Rights issue.
    08 Dec 2023 John Michailidis Issued 200,000 $4,400
    Rights issue.
    08 Dec 2023 David Brookes Issued 140,000 $3,080
    Rights issue.
    08 Dec 2023 David Brookes Issued 725,716 $15,965
    Rights issue.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr David Lionel Brookes Executive ChairmanExecutive Director Jun 2022
    Dr. Brookes has extensive experience in the health and biotechnology industries, first becoming involved in the biotechnology sector in the late 1990's as an analyst. Dr. Brookes has since held Board positions in a number of ASX listed biotechnology companies. Dr. Brookes maintains roles as a clinician and as a biotechnology industry consultant. He is a Member of the audit and risk management committee Member of the remuneration and nominations committee.
    Mr John Michailidis Chief Operating OfficerExecutive Director Oct 2023
    Mr Michailidis has more than 30 years of pharmaceutical experience. John is currently the Chief Operating Officer of Anatara and the Managing Director of JEM Pharmaceuticals Pty Ltd. He has gained experience in several senior and executive positions throughout his career, including as Non-Executive Director of Factor Therapeutics Pty Ltd and Australian Diabetes Educators Association, the Chair of Access Community Health, Managing Director of Teva Pharma Australia Pty Ltd and Business Director and Global Head of the Nephrology/Oncology Franchise for F. Hoffman La Roche. John also has CEO experience with growth-stage pharmaceutical companies including Orphan Australia Pty Ltd, Avipep Pty Ltd and Roche Korea Ltd.
    Mr Nicholas William Haslam Non-Executive Director Dec 2022
    Mr Haslam is a member of audit and risk management committee Member of the remuneration and nominations committee.
    Mr Stephen (Steve) Denaro Company Secretary
    -
    Mr Steven Lydeamore Chief Executive Officer Dec 2018
    -
    Simon Erskine Chief Development Officer
    -
    Steven Lydeamore Chief Executive Officer
    -
    John Michailidis Chief Operating Officer
    -
    Stephen (Steve) Denaro Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Rtl Group Investments Pty Ltd <The Rtl Investment A/C> 12,542,857 10.46%
    Ubs Nominees Pty Ltd 8,494,808 7.08%
    Scintilla Strategic Investments Limited 6,357,142 5.30%
    Parma Corporation Pty Ltd 4,667,681 3.89%
    Myeng Pty Ltd 3,580,211 2.99%
    Mr Bertrand Lalanne 3,300,000 2.75%
    Himstedt & Co Pty Ltd <The Himstedt Family A/C> 3,142,857 2.62%
    Calama Holdings Pty Ltd <Mambat Super Fund A/C> 2,663,987 2.22%
    Mr Michael Andrew Whiting + Mrs Tracey Anne Whiting <Whiting Family S/F A/C> 2,500,000 2.08%
    Symington Pty Ltd 2,100,000 1.75%
    Mr Samuel Francis Hunter 2,080,729 1.74%
    Octifil Pty Ltd 2,000,000 1.67%
    Mr Brendan Phyland 1,894,042 1.58%
    Candour Asset Management Pty Ltd 1,548,056 1.29%
    Gp Securities Pty Ltd 1,500,000 1.25%
    Slade Technologies Pty Ltd <Embrey Family Superfund A/C> 1,500,000 1.25%
    Longridge Partners Pty Ltd 1,400,000 1.17%
    Toucan Trading Pty Ltd 1,371,429 1.14%
    Dr David Lionel Brookes + Mrs Elisabeth Brookes <Dr Dl Brookes Persnl S/F A/C> 1,242,858 1.04%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 1,096,345 0.91%

    Profile

    since

    Note